As news of substantial negotiations for a potential licensing agreement surfaced, shares of BioRestorative Therapies, Inc. (NASDAQ: BRTX) have surged on the US stock charts. At the latest check during the current market session, BRTX stock was trading up 62.55%, reaching $2.17.
Progress In Regenerative Medicine
BioRestorative (BRTX) said today that it has entered into significant negotiations for the licensing of BioRestorative’s allogeneic, commercially available ThermoStem metabolic intellectual property with an unidentified regenerative medicine business.
Prior peer-reviewed preclinical research carried out in association with the University of Utah School of Medicine demonstrated the existence of a clonogenic population of metabolically active adult human brown adipose tissue (BAT) stem cells that are able to expand and differentiate into many lineages in vitro. These cells can functionally differentiate into metabolically active brown adipocytes.
Additionally, preclinical results demonstrated that multipotent brown adipose-derived stem cells (BADSCs) induced to differentiate into brown adipocytes exhibit mature functional properties, including enhanced mitochondrial activity, a critical functional characteristic of BAT. Brown adipogenic potential stem cells (BADSCs) offer a potentially effective novel treatment option for obesity and associated metabolic problems.
Novel Therapeutic Strategies
To further explore this potential, BioRestorative has developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery. Data from high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by the 3D scaffold showed significant reductions in weight, triglyceride, and blood glucose levels compared to saline-only injected controls.
However, no assurances can be made that a licensing agreement will be finalized, whether on commercially reasonable terms or otherwise. BioRestorative does not plan to make additional announcements regarding the license unless and until an agreement is reached.
Industry Interest And Future Prospects
It has been intriguing to observe the scale, scope, and speed with which potential license partners have shown interest in BioRestorative’s proprietary off-the-shelf ThermoStem platform. Pioneering animal studies indicated that BADSCs could potentially mitigate weight gain and hyperglycemia associated with high-fat diets.
Furthermore, the 3D scaffolds, capable of maintaining viable transplanted cells for at least five weeks post-implantation, have attracted the interest of commercial-stage regenerative medicine companies, with whom BioRestorative is now engaged in significant licensing discussions.
